The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma

The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo 68Ga-grazytracer PET at baseline and after one course of immunotherapy.

Inclusion criteria

• Age > 18 years, regardless of gender.
• Histopathologically confirmed diagnosis of T-NK cell lymphoma.
• Newly diagnosed and untreated patients or refractory/relapsed patients preparing to undergo immunotherapy.
• Availability of complete clinicopathological and follow-up data.
• Signed and dated informed consent form.

Exclusion criteria

• Patients who have previously received anti-tumor therapy.
• Patients with a history of other malignancies.
• Incomplete clinical information or imaging data.
• Concurrent other malignant tumors.
• Patients with severe medical conditions deemed unsuitable for participation in this clinical study by the investigator, such as severe cardiopulmonary insufficiency or severe hepatic and renal dysfunction.
• Poor compliance.